Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort

Journal of the National Cancer Institute

Volumn 102, Issue 23, 2010, Pages 1794-1804

  Safaeian, Mahboobeh ^a   Quint, Koen ^b   Schiffman, Mark ^a   Rodriguez, Ana Cecilia ^c   Wacholder, Sholom ^a   Herrero, Rolando ^c   Hildesheim, Allan ^a   Viscidi, Raphael P ^d   Quint, Wim ^b   Burk, Robert D ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DDL DIAGNOSTIC LABORATORY   (Netherlands)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ARTICLE; BACTERIUM DETECTION; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COSTA RICA; DOT HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COHORT STUDIES; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DNA, BACTERIAL; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 78649811810     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq436     Document Type: Article

References (32)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4):244-265. (Pubitemid 34293391)
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-19.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590): 890-907.
4. Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer. 2004;111(3):431-439.
5. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia tracho-matis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis. 2002;185(3): 324-331.
6. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA. 2001;285(1):47-51. (Pubitemid 32042715)
7. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000;85(1):35-39.
8. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer. 2007;120(3):650-655.
9. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997;89(17):1293-1299.
10. Castle PE, Escoffery C, Schachter J, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Transm Dis. 2003;30(7):575-580.
11. Yoshikawa H, Nagata C, Noda K, et al. Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer. 1999;80(3-4):621-624.
12. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neo-plasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica. 2004;15(2):75-89.
13. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997;1(5):362-375. (Pubitemid 27428425)
14. Wang SS, Bratti MC, Rodriguez AC, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199(1):20-30.
15. Rodriguez AC, Castle PE, Smith JS, et al. A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Sex Transm Infect. 2003;79(6):460-465.
16. De SS, Mbisa G, Perez-Alvarez S, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis. 2009;199(10):1449-1456.
17. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010; 102(5):315-324.
18. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002;68(3):417-423.
19. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997;35(6):1304-1310.
20. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13(2):324-327.
21. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human pap-illomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003;89(7):1248-1254.
22. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervico-vaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186(6): 737-742.
23. Quint K, Porras C, Safaeian M, et al. Evaluation of a novel PCR-based assay for detection and identifcation of Chlamydia trachomatis serovars in cervical specimens. J Clin Microbiol. 2007;45(12):3986-3991.
24. Quint KD, Van Doorn LJ, Kleter B, et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identifcation of Chlamydia trachomatis serovars. J Mol Diagn. 2007;9(5):631-638.
25. Wacholder S. Chapter 18: Statistical issues in the design and analysis of studies of human papillomavirus and cervical neoplasia. J Natl Cancer Inst Monogr. 2003;31:125-130.
26. Institute of Medicine. The Hidden Epidemic, Confronting Sexually Transmitted Diseases.Washington, DC: National Academy Press; 1997.
27. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am J Epidemiol. 2002;156(8):687-692.
28. Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101(4):371-374.
29. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillo-maviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol. 2007;88(3):814-822.
30. Matsumoto K, Yasugi T, Oki A, et al. Are smoking and chlamydial infection risk factors for CIN? Different results after adjustment for HPV DNA and antibodies. Br J Cancer. 2003;89(5):831-833.
31. Schiffman M, Safaeian M, Wentzensen N. The use of human papilloma-virus seroepidemiology to inform vaccine policy. Sex Transm Dis. 2009; 36(11):675-679.
32. Smith JS, Munoz N, Franceschi S, Eluf-Neto J, Herrero R, Peeling RW. Chlamydia trachomatis and cervical squamous cell carcinoma. JAMA. 2001;285(13):1704-1706.